Literature DB >> 36091579

Programmable endonuclease combined with isothermal polymerase amplification to selectively enrich for rare mutant allele fractions.

Junman Chen1,2,3, Tian Qiud4, Michael G Mauk3, Zheng Su5, Yaguang Fan6, Dennis J Yuan2, Qinghua Zhou7, Youlin Qiao5, Haim H Bau3, Jianming Ying4, Jinzhao Song2,3.   

Abstract

Liquid biopsy is a highly promising method for non-invasive detection of tumor-associated nucleic acid fragments in body fluids but is challenged by the low abundance of nucleic acids of clinical interest and their sequence homology with the vast background of nucleic acids from healthy cells. Recently, programmable endonucleases such as clustered regularly interspaced short palindromic repeat (CRISPR) associated protein (Cas) and prokaryotic Argonautes have been successfully used to remove background nucleic acids and enrich mutant allele fractions, enabling their detection with deep next generation sequencing (NGS). However, the enrichment level achievable with these assays is limited by futile binding events and off-target cleavage. To overcome these shortcomings, we conceived a new assay (Programmable Enzyme-Assisted Selective Exponential Amplification, PASEA) that combines the cleavage of wild type alleles with concurrent polymerase amplification. While PASEA increases the numbers of both wild type and mutant alleles, the numbers of mutant alleles increase at much greater rates, allowing PASEA to achieve an unprecedented level of selective enrichment of targeted alleles. By combining CRISPR-Cas9 based cleavage with recombinase polymerase amplification, we converted samples with 0.01% somatic mutant allele fractions (MAFs) to products with 70% MAFs in a single step within 20 min, enabling inexpensive, rapid genotyping with such as Sanger sequencers. Furthermore, PASEA's extraordinary efficiency facilitates sensitive real-time detection of somatic mutant alleles at the point of care with custom designed Exo-RPA probes. Real-time PASEA' performance was proved equivalent to clinical amplification refractory mutation system (ARMS)-PCR and NGS when testing over hundred cancer patients' samples. This strategy has the potential to reduce the cost and time of cancer screening and genotyping, and to enable targeted therapies in resource-limited settings.

Entities:  

Keywords:  CRISPR-Cas9; Liquid biopsy; Mutant allele enrichment; Mutation detection; Nucleic acid diagnostics; Point-of-care testing; Programmable endonuclease; Recombinase polymerase amplification

Year:  2021        PMID: 36091579      PMCID: PMC9454931          DOI: 10.1016/j.cclet.2021.11.065

Source DB:  PubMed          Journal:  Chin Chem Lett        ISSN: 1001-8417            Impact factor:   8.455


  28 in total

Review 1.  CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea.

Authors:  Rotem Sorek; Victor Kunin; Philip Hugenholtz
Journal:  Nat Rev Microbiol       Date:  2008-03       Impact factor: 60.633

2.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

3.  Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA.

Authors:  Amin Aalipour; Jonathan C Dudley; Seung-Min Park; Surya Murty; Jacob J Chabon; Evan A Boyle; Maximilian Diehn; Sanjiv S Gambhir
Journal:  Clin Chem       Date:  2017-10-16       Impact factor: 8.327

4.  Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification.

Authors:  Lucia R Wu; Sherry X Chen; Yalei Wu; Abhijit A Patel; David Yu Zhang
Journal:  Nat Biomed Eng       Date:  2017-09-04       Impact factor: 25.671

5.  Smartphone-Based Mobile Detection Platform for Molecular Diagnostics and Spatiotemporal Disease Mapping.

Authors:  Jinzhao Song; Vikram Pandian; Michael G Mauk; Haim H Bau; Sara Cherry; Laurence C Tisi; Changchun Liu
Journal:  Anal Chem       Date:  2018-03-22       Impact factor: 6.986

6.  DNA-guided DNA interference by a prokaryotic Argonaute.

Authors:  Daan C Swarts; Matthijs M Jore; Edze R Westra; Yifan Zhu; Jorijn H Janssen; Ambrosius P Snijders; Yanli Wang; Dinshaw J Patel; José Berenguer; Stan J J Brouns; John van der Oost
Journal:  Nature       Date:  2014-02-16       Impact factor: 49.962

7.  Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations.

Authors:  Qian Liu; Xiang Guo; Guanhua Xun; Zhonglei Li; Yuesheng Chong; Litao Yang; Hongxia Wang; Fengchun Zhang; Shukun Luo; Li Cui; Pengshu Zhao; Xingyu Ye; Heshan Xu; Hui Lu; Xiao Li; Zixin Deng; Kai Li; Yan Feng
Journal:  Nucleic Acids Res       Date:  2021-07-21       Impact factor: 16.971

8.  Highly specific enrichment of rare nucleic acid fractions using Thermus thermophilus argonaute with applications in cancer diagnostics.

Authors:  Jinzhao Song; Jorrit W Hegge; Michael G Mauk; Junman Chen; Jacob E Till; Neha Bhagwat; Lotte T Azink; Jing Peng; Moen Sen; Jazmine Mays; Erica L Carpenter; John van der Oost; Haim H Bau
Journal:  Nucleic Acids Res       Date:  2020-02-28       Impact factor: 16.971

9.  Quantitative and sensitive detection of GNAS mutations causing mccune-albright syndrome with next generation sequencing.

Authors:  Satoshi Narumi; Kumihiro Matsuo; Tomohiro Ishii; Yusuke Tanahashi; Tomonobu Hasegawa
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

10.  Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Authors:  A K Krug; D Enderle; C Karlovich; T Priewasser; S Bentink; A Spiel; K Brinkmann; J Emenegger; D G Grimm; E Castellanos-Rizaldos; J W Goldman; L V Sequist; J-C Soria; D R Camidge; S M Gadgeel; H A Wakelee; M Raponi; M Noerholm; J Skog
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.